MarketCapExport financials
Mettler-Toledo International (MTD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Mettler-Toledo International Income Statement 2025-2007 | MTD
Brief overview of income trends at Mettler-Toledo International
The overview follows changes across a five-year period. Revenue reported by Mettler-Toledo International was 3.1 billion dollars at the beginning of the period and 4 billion dollars at the end. The five-year change reached +30.5%, while CAGR stood at 5.5%. Sales increased steadily, although without strong acceleration.
Gross profit changed from $1.8 billion to $2.4 billion (+32.7%). The gross margin was 58.4% at the start and 59.4% at the end. The relationship between gross profit and revenue changed only slightly.
The operating result measured by EBITDA moved from 42 million dollars to 51.1 million dollars, or +21.6%. The operating result changed at a rate similar to sales. At the operating-margin level, the figure shifted from 1.4% to 1.3%. Operating efficiency did not change materially.
Net profit was 603 million dollars at the start and 869 million dollars at the end. Net profitability strengthened faster than the top line.
The five-year change in capitalization reached +1.8%: from 27.9 billion dollars to 28.4 billion dollars. Investors responded cautiously to the improvement in the business.
Financial takeaway
The five-year picture requires weighing both strengths and weaknesses. Key strengths include net-income growth, consistent operating efficiency and revenue expansion. The main areas of concern are a low EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
28.4 B | 29.9 B | 25.7 B | 33.9 B | 34.1 B | 27.9 B | 19.1 B | 16 B | 17.4 B | 11.2 B | 8.66 B | 8.78 B | 7.47 B | 6.57 B | 5.61 B | 3.74 B | 2.54 B | 3.56 B | - |
Shares |
20.6 M | 21.2 M | 21.8 M | 22.5 M | 23.1 M | 23.9 M | 24.6 M | 25.2 M | 25.7 M | 26.5 M | 27.7 M | 28.9 M | 29.9 M | 31 M | 31.9 M | 33.3 M | 33.7 M | 34.3 M | - |
Historical Prices |
1.38 K | 1.41 K | 1.18 K | 1.51 K | 1.47 K | 1.17 K | 757 | 638 | 675 | 427 | 313 | 304 | 246 | 213 | 176 | 112 | 75.4 | 104 | 98.9 |
Net Income |
869 M | 863 M | 789 M | 873 M | 769 M | 603 M | 561 M | 513 M | 376 M | 384 M | 353 M | 338 M | 306 M | 291 M | 269 M | 232 M | 173 M | 203 M | - |
Revenue |
4.03 B | 3.87 B | 3.79 B | 3.92 B | 3.72 B | 3.09 B | 3.01 B | 2.94 B | 2.73 B | 2.51 B | 2.4 B | 2.49 B | 2.38 B | 2.34 B | 2.31 B | - | - | - | - |
Gross Profit |
2.39 B | 2.33 B | 2.24 B | 2.31 B | 2.17 B | 1.8 B | 1.74 B | 1.68 B | 1.57 B | 1.44 B | 1.35 B | 1.36 B | 1.28 B | 1.24 B | 1.22 B | 1.04 B | 889 M | 993 M | - |
Interest Expense |
68.5 M | 74.6 M | 77.4 M | 55.4 M | 43.2 M | 38.6 M | 37.4 M | 34.5 M | 32.8 M | 28 M | 27.5 M | 24.5 M | 22.7 M | 22.8 M | 23.2 M | 20.1 M | 25.1 M | 25.4 M | - |
EBITDA |
51.1 M | 50.4 M | 49 M | 46.8 M | 45 M | 42 M | 778 M | 731 M | 657 M | 583 M | 532 M | 507 M | 473 M | 444 M | 396 M | 29.7 M | 29.6 M | 29 M | - |
Operating Expenses |
- | - | - | - | - | - | 1.01 B | 1 B | 959 M | 889 M | 851 M | 881 M | 834 M | 818 M | 840 M | - | - | - | - |
General and Administrative Expenses |
998 M | 936 M | 904 M | 938 M | 944 M | 820 M | - | - | - | - | - | - | - | - | - | 589 M | 505 M | 580 M | - |
All numbers in USD currency
Quarterly Income Statement Mettler-Toledo International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
20.3 M | 20.5 M | 20.7 M | 20.9 M | 22.1 M | 21.1 M | 20.1 M | 21.4 M | 22.1 M | 21.8 M | 21.9 M | 22.1 M | 22.8 M | 22.4 M | 22.6 M | 22.8 M | 22.8 M | 23.1 M | 23.2 M | 23.4 M | 23.6 M | 23.9 M | 23.9 M | 24 M | 24.2 M | 24.5 M | 24.7 M | 24.9 M | 25 M | 25.1 M | 25.3 M | 25.5 M | 25.6 M | 25.6 M | 25.8 M | 25.9 M | 26.1 M | 26.4 M | 26.6 M | 26.9 M | 27.2 M | 27.5 M | 27.8 M | 28.1 M | 28.4 M | 28.7 M | 29.1 M | 29.4 M | 29.6 M | 29.8 M | 30.1 M | 30.3 M | 30.5 M | 30.8 M | 31.3 M | 31.5 M | 31.5 M | 30.8 M | 31.3 M | 31.5 M | 33.2 M | 33.5 M |
Net Income |
169 M | 217 M | 202 M | 164 M | - | 212 M | 233 M | 178 M | - | 202 M | 214 M | 188 M | - | 221 M | 212 M | 174 M | 174 M | 204 M | 185 M | 150 M | 216 M | 162 M | 127 M | 98.1 M | 193 M | 129 M | 127 M | 112 M | 181 M | 127 M | 111 M | 93.3 M | 77 M | 376 M | 376 M | 92.5 M | 138 M | 384 M | 384 M | 384 M | 123 M | 353 M | 353 M | 353 M | 121 M | 338 M | 338 M | 338 M | 110 M | 306 M | 306 M | 306 M | 105 M | 291 M | 291 M | 291 M | 94.3 M | 269 M | 269 M | 269 M | 62.1 M | 51.3 M |
Revenue |
947 M | 1.03 B | 983 M | 884 M | - | 955 M | 1.03 B | 926 M | - | 942 M | 982 M | 929 M | - | 986 M | 978 M | 898 M | - | 952 M | 924 M | 804 M | 938 M | 807 M | 691 M | 649 M | 844 M | 754 M | 731 M | 679 M | 818 M | 735 M | 722 M | 661 M | 778 M | 699 M | 654 M | 595 M | 710 M | 651 M | 608 M | 540 M | 674 M | 604 M | 582 M | 536 M | 697 M | 629 M | 609 M | 551 M | 684 M | 592 M | 579 M | 524 M | 657 M | 579 M | 570 M | 535 M | 648 M | 601 M | 561 M | 499 M | - | - |
Gross Profit |
556 M | 609 M | 580 M | 526 M | - | 572 M | 650 M | 548 M | - | 560 M | 584 M | 547 M | - | 585 M | 572 M | 520 M | - | 556 M | 537 M | 472 M | 559 M | 470 M | 398 M | 374 M | 498 M | 435 M | 420 M | 388 M | 478 M | 419 M | 413 M | 375 M | 456 M | 401 M | 376 M | 343 M | 419 M | 369 M | 348 M | 300 M | 391 M | 340 M | 323 M | 299 M | 394 M | 344 M | 328 M | 293 M | 375 M | 319 M | 309 M | 279 M | 357 M | 308 M | 299 M | 277 M | 346 M | 308 M | 299 M | 277 M | 256 M | 247 M |
Interest Expense |
17 M | 17.7 M | 16.8 M | 16.7 M | - | 18.6 M | 17.2 M | 19.2 M | - | 20.3 M | 19.2 M | 18.2 M | - | 14.5 M | 12.8 M | 11.3 M | - | 11.8 M | 10.4 M | 9.47 M | - | 9.31 M | 9.58 M | 10.2 M | - | 9.8 M | 8.88 M | 9.09 M | - | 9 M | 8.31 M | 8.36 M | - | 8.25 M | 8.17 M | 7.74 M | - | 7.17 M | 6.87 M | 6.58 M | - | 7.03 M | 6.94 M | 6.72 M | - | 5.99 M | 5.96 M | 5.67 M | - | 5.56 M | 5.54 M | 5.4 M | - | 5.57 M | 5.71 M | 5.82 M | - | 5.89 M | 5.69 M | 5.71 M | 4.79 M | 4.71 M |
EBITDA |
13.2 M | 12.7 M | 12.9 M | 12.5 M | - | 12.8 M | 13.3 M | 12.5 M | - | 7 M | 6.9 M | 12 M | - | 6.7 M | 6.6 M | 11.9 M | - | 33.4 M | 6.2 M | 10.9 M | - | 30.9 M | 20.3 M | 10.1 M | - | 29.3 M | 19.4 M | 9.77 M | - | 27.9 M | 18.6 M | 9.16 M | - | 24.4 M | 15.9 M | 7.97 M | - | 24.5 M | 16.1 M | 8.12 M | - | 25 M | 16.7 M | 8.3 M | - | 25.5 M | 16.9 M | 8.42 M | - | 26 M | 17.4 M | 8.88 M | - | 24.3 M | 16.1 M | 7.78 M | - | 23.4 M | 14.9 M | 7.38 M | 22.3 M | 14.5 M |
General and Administrative Expenses |
258 M | 248 M | 247 M | 243 M | - | 229 M | 263 M | 234 M | - | 217 M | 229 M | 235 M | - | 233 M | 242 M | 235 M | - | 241 M | 239 M | 222 M | - | 205 M | 190 M | 199 M | - | 203 M | 205 M | 204 M | - | 202 M | 208 M | 201 M | - | 207 M | 196 M | 186 M | - | 188 M | 188 M | 169 M | - | 176 M | 175 M | 173 M | - | 186 M | 183 M | 172 M | - | 173 M | 173 M | 166 M | - | 171 M | 170 M | 168 M | - | 186 M | 172 M | 161 M | 145 M | 144 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Mettler-Toledo International (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M |  Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |